Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: January 27, 2023

Details for Patent: 8,093,295

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,093,295 protect, and when does it expire?

Patent 8,093,295 protects ZOLINZA and is included in one NDA.

This patent has forty-one patent family members in twenty-three countries.

Summary for Patent: 8,093,295
Title:Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Inventor(s): Wong; Jeannie Chow (Jersey City, NJ), Cohen; Benjamin Max (Cranford, NJ), Cote; Aaron S. (West Windsor, NJ), Dienemann; Erik A. (Metuchen, NJ), Gallagher; Kimberly (Green Lane, PA), Ikeda; Craig (Harleysville, PA), Moser; Justin (Collegeville, PA), Rajniak; Pavol (Lansdale, PA), Reed; Robert A. (Line Lexington, PA), Sell; Brian (Royersford, PA), Starbuck; Cindy (Doylestown, PA), Tung; Hsien-Hsin (Grayslake, IL), Wang; Qingxi (Ambler, PA), Capodanno; Vincent R. (Hillsborough, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:11/663,165
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,093,295

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,093,295

PCT Information
PCT FiledMay 16, 2006PCT Application Number:PCT/US2006/018795
PCT Publication Date:November 30, 2006PCT Publication Number: WO2006/127321

International Family Members for US Patent 8,093,295

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055953 See Plans and Pricing
Argentina 095159 See Plans and Pricing
Australia 2006249440 See Plans and Pricing
Australia 2009201650 See Plans and Pricing
Australia 2009201652 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.